Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Doses of HRS-7535 in Obese Subjects
NCT06621316Phase 2Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of HRS-7535 in obesity (12 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: Number of Adverse Events at 24 weeks. Started Oct 2024; status: completed.
02
Drugs
HRS-7535
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06621316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621316.